The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of cetuximab + FOLFIRI versus bevacizumab + FOLFIRI in the first-line treatment of RAS wild-type metastatic colorectal cancer in China.
 
Ilse Van Oostrum
Employment - Ingress Health
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Merck KGaA; Pfizer; Sanofi
Research Funding - Amgen; AstraZeneca; Janssen; Merck KGaA; Pfizer; Sanofi
 
Yannan Hu
Employment - Ingress Health
 
Zijiao Yuan
Employment - Ingress Health
 
Michael Schlichting
Employment - Merck KGaA
 
Libo Tao
Consulting or Advisory Role - Institute of Health Policy & Technology Assessment, Health Science Center, Peking University
Speakers' Bureau - Institute of Health Policy & Technology Assessment, Health Science Center, Peking University
Research Funding - Institute of Health Policy & Technology Assessment, Health Science Center, Peking University
Travel, Accommodations, Expenses - Institute of Health Policy & Technology Assessment, Health Science Center, Peking University
 
Chris P. Pescott
Employment - Merck KGaA